IBRAHIM TAHA ALDOSS M.D.
Prescription History 1861692485
Internal Medicine - Hematology in Duarte, CA
Medicare Part D Prescription History
Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for IBRAHIM TAHA ALDOSS M.D., an active Hematology specialist practicing in Duarte, CA. Our medical registry currently tracks 4 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 86 documented patient claims. Among these therapy options, the most frequently utilized medication is Jakafi, which accounts for 41 claims alone. Use the table below to sort by claims, cost, or utilization compared with the state average; select any medication for its full profile.
| Medication | Prescriptions (2023)Rx (2023) | Avg Cost per FillCost / Fill | Vs. Other CA PrescribersVs. CA Avg |
|---|---|---|---|
| JakafiRuxolitinib Phosphate | 41 | $13,940.25▼ below CA avg | ▲ More than typical |
About Jakafi: This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). Show more ▾ It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system). In 2023, this provider wrote 41 Medicare prescriptions for Jakafi, about 1.6 times the volume of the typical California prescriber of this medication (26). Medicare paid an average of $13,940.25 per fill, versus $15,930.09 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 41 30-Day Fills standardized to 30-day supplies 1,222 Days of Medication total across all patients in 2023 | |||
| TasignaNilotinib Hcl | 21 | $6,801.30▼ below CA avg | ▲ More than typical |
About Tasigna: Nilotinib is used to treat a certain type of blood cancer (chronic myelogenous leukemia-CML). Show more ▾ It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 21 Medicare prescriptions for Tasigna, about 1.4 times the volume of the typical California prescriber of this medication (15). Medicare paid an average of $6,801.30 per fill, versus $15,310.65 statewide. How often this provider prescribes it This provider prescribes this medication more often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 21 30-Day Fills standardized to 30-day supplies 588 Days of Medication total across all patients in 2023 | |||
| RevlimidLenalidomide | 12 | $18,018.23▼ below CA avg | ▼ Less than typical |
About Revlimid: Lenalidomide is used to treat various types of cancers. Show more ▾ It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication. A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA. In 2023, this provider wrote 12 Medicare prescriptions for Revlimid, about a third of the volume of the typical California prescriber of this medication (37). Medicare paid an average of $18,018.23 per fill, versus $18,322.70 statewide. How often this provider prescribes it This provider prescribes this medication less often than the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill This provider's average cost per fill is below the CA average for this medication. 12 30-Day Fills standardized to 30-day supplies 336 Days of Medication total across all patients in 2023 | |||
| ScemblixAsciminib Hydrochloride | 12 | $22,654.94 | ≈ Typical |
About Scemblix: Asciminib is used to treat a certain type of cancer (chronic myeloid leukemia-CML). Show more ▾ Asciminib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. In 2023, this provider wrote 12 Medicare prescriptions for Scemblix, about 75% of the volume of the typical California prescriber of this medication (16). Medicare paid an average of $22,654.94 per fill, versus $22,113.97 statewide. How often this provider prescribes it This provider's prescribing volume for this medication is in line with the average CA prescriber. Utilization reflects practice size as well as clinical preference. What Medicare paid per fill Gross Part D cost per fill; not the patient's out-of-pocket price. 12 30-Day Fills standardized to 30-day supplies 360 Days of Medication total across all patients in 2023 | |||
About this data. The prescription history for IBRAHIM TAHA ALDOSS M.D. is compiled from the Centers for Medicare & Medicaid Services (CMS) Medicare Part D Prescriber Public Use File for calendar year 2023, the most recent federal release. Figures cover prescriptions filled for Medicare Part D beneficiaries only; prescriptions under private insurance, Medicaid, or self-pay plans are not included. Because prescribing decisions are generally consistent across coverage types, this record offers a useful view of the overall Hematology prescribing approach at this Duarte, CA practice.
Reading the costs. Drug costs are gross amounts paid to pharmacies under Part D, including both plan and beneficiary payments. They are not the price a patient pays at the pharmacy counter. Medications with fewer than 11 claims are excluded from the federal source data, and state comparisons use the average volume among CA prescribers of the same medication. Always confirm current medications and costs directly with the provider and your plan.
